Agmatine Shows Promise in Neuropathy Pain Reduction, Study Finds

330

Henderson, NV— Agmatine supplementation can effectively mitigate painful symptoms in neuropathies associated with small fiber neuropathy, according to a study published in the journal Ingredients.

Small fiber neuropathy (SFN), according to a press release on the study, is triggered by the damage of small-diameter somatic nerve fibers, which carry information relating to pain and temperature, and of small autonomic fibers involved in regulating sympathetic and parasympathetic nervous system functions. SFN is associated with many different types of neuropathy including metabolic, autoimmune, inflammatory, infectious, and toxic etiologies, as well as with fibromyalgia.

More than 10 million people in the U.S. alone are affected by SFN, the press release says. Currently, first-line treatments for neuropathic pain includes anticonvulsants and antidepressants, but only about 50% pain relief is achieved in less than half of patients, and many experience serious side effects. However, a team of scientists from JFK Neuroscience Institute, JFK Medical Center, in New Jersey, led by Michael L. Rosenberg, have found that supplementation with agmatine can significantly reduce neuropathic pain intensity. The study used G-Agmatine brand, provided by Gilad&Gilad LLC.

Related: Kratom for Chronic Pain?
My Meat-Free Journey to Health
Mental Health Crisis: Stress, Anxiety, Poor Sleep & COVID

The researchers conducted an open-label consecutive case series study to evaluate the effectiveness of agmatine. Participants diagnosed with painful SFN and autonomic dysfunctions were treated with 2.67g/day agmatine sulfate, as AgmaSet capsules containing G-Agmatine, for a period of two months. Participants answered a neuropathic pain questionnaire both at baseline and at the end of the treatment period. 11 patients completed the study. None showed any serious side effects, and all patients showed improvement in neuropathic pain to a varied extent. The average decrease in pain intensity was 46.4%.

Larger controlled studies are expected to establish agmatine sulfate as a preferred treatment for neuropathies, the press release says.

LEAVE A REPLY

Please enter your comment!
Please enter your name here